JP2022546609A5 - - Google Patents
Info
- Publication number
- JP2022546609A5 JP2022546609A5 JP2022514998A JP2022514998A JP2022546609A5 JP 2022546609 A5 JP2022546609 A5 JP 2022546609A5 JP 2022514998 A JP2022514998 A JP 2022514998A JP 2022514998 A JP2022514998 A JP 2022514998A JP 2022546609 A5 JP2022546609 A5 JP 2022546609A5
- Authority
- JP
- Japan
- Prior art keywords
- composite
- seq
- complex
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025065195A JP2025108559A (ja) | 2019-09-06 | 2025-04-10 | ウイルス感染症の治療のための組成物及び方法 |
Applications Claiming Priority (21)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962897036P | 2019-09-06 | 2019-09-06 | |
| US62/897,036 | 2019-09-06 | ||
| US201962941405P | 2019-11-27 | 2019-11-27 | |
| US62/941,405 | 2019-11-27 | ||
| US201962948143P | 2019-12-13 | 2019-12-13 | |
| US62/948,143 | 2019-12-13 | ||
| US202062959857P | 2020-01-10 | 2020-01-10 | |
| US62/959,857 | 2020-01-10 | ||
| US202062966500P | 2020-01-27 | 2020-01-27 | |
| US62/966,500 | 2020-01-27 | ||
| US202062970491P | 2020-02-05 | 2020-02-05 | |
| US62/970,491 | 2020-02-05 | ||
| US202062984705P | 2020-03-03 | 2020-03-03 | |
| US62/984,705 | 2020-03-03 | ||
| US202062988304P | 2020-03-11 | 2020-03-11 | |
| US62/988,304 | 2020-03-11 | ||
| US202063032488P | 2020-05-29 | 2020-05-29 | |
| US63/032,488 | 2020-05-29 | ||
| US202063062377P | 2020-08-06 | 2020-08-06 | |
| US63/062,377 | 2020-08-06 | ||
| PCT/US2020/049772 WO2021046549A1 (en) | 2019-09-06 | 2020-09-08 | Compositions and methods for the treatment of viral infections |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025065195A Division JP2025108559A (ja) | 2019-09-06 | 2025-04-10 | ウイルス感染症の治療のための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022546609A JP2022546609A (ja) | 2022-11-04 |
| JP2022546609A5 true JP2022546609A5 (enExample) | 2023-09-15 |
| JP7667139B2 JP7667139B2 (ja) | 2025-04-22 |
Family
ID=74852729
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022514998A Active JP7667139B2 (ja) | 2019-09-06 | 2020-09-08 | ウイルス感染症の治療のための組成物及び方法 |
| JP2025065195A Pending JP2025108559A (ja) | 2019-09-06 | 2025-04-10 | ウイルス感染症の治療のための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025065195A Pending JP2025108559A (ja) | 2019-09-06 | 2025-04-10 | ウイルス感染症の治療のための組成物及び方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US20210220478A1 (enExample) |
| EP (1) | EP4025256A4 (enExample) |
| JP (2) | JP7667139B2 (enExample) |
| KR (1) | KR20220088527A (enExample) |
| CN (2) | CN114980933B (enExample) |
| AU (2) | AU2020342649B2 (enExample) |
| CA (1) | CA3153359A1 (enExample) |
| CL (1) | CL2022000531A1 (enExample) |
| CO (1) | CO2022003078A2 (enExample) |
| CR (1) | CR20220138A (enExample) |
| EC (1) | ECSP22026797A (enExample) |
| IL (1) | IL290792B1 (enExample) |
| MX (1) | MX2022002728A (enExample) |
| PE (1) | PE20221443A1 (enExample) |
| PH (1) | PH12022550505A1 (enExample) |
| TW (1) | TWI861205B (enExample) |
| WO (1) | WO2021046549A1 (enExample) |
| ZA (1) | ZA202203681B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021004266A2 (pt) | 2018-09-06 | 2021-08-03 | Cidara Therapeutics, Inc. | conjugados, população de conjugados, composição farmacêutica e métodos para o tratamento de um sujeito com uma infecção viral e para o tratamento profilático |
| TWI861205B (zh) | 2019-09-06 | 2024-11-11 | 美商席達拉醫療有限公司 | 用於治療病毒感染之組合物及方法 |
| JP2023511956A (ja) * | 2020-01-24 | 2023-03-23 | レゲネロン ファーマシューティカルス，インコーポレーテッド | タンパク質－抗ウイルス化合物コンジュゲート |
| WO2022032188A1 (en) | 2020-08-06 | 2022-02-10 | Cidara Therapeutics, Inc. | Methods for the synthesis of protein-drug conjugates |
| US20230364251A1 (en) | 2020-08-06 | 2023-11-16 | Cidara Therapeutics, Inc. | Methods for the synthesis of protein-drug conjugates |
| CA3211494A1 (en) | 2021-03-11 | 2022-09-15 | Leslie W. Tari | Protein-drug conjugates for antiviral therapy |
| US20250144220A1 (en) * | 2021-12-30 | 2025-05-08 | Suzhou Ark Biopharmaceutical Co., Ltd. | Conjugate for preventing and treating viral infections and use thereof |
| KR20250048157A (ko) * | 2022-07-05 | 2025-04-07 | 시다라 세라퓨틱스, 인코포레이티드 | Cd73의 억제제를 포함하는 fc 컨쥬게이트 및 이의 용도 |
| CN119215189A (zh) | 2023-06-29 | 2024-12-31 | 上海爱科百发生物医药技术股份有限公司 | 用于预防和治疗病毒感染的偶联物及其用途 |
| WO2025064869A2 (en) * | 2023-09-20 | 2025-03-27 | Cidara Therapeutics, Inc. | Compositions and methods for the treatment of cancer |
| TW202527994A (zh) * | 2023-12-08 | 2025-07-16 | 大陸商蘇州拓界醫藥有限公司 | 一種抗病毒偶聯物 |
| WO2025157263A1 (zh) * | 2024-01-26 | 2025-07-31 | 浙江养生堂天然药物研究所有限公司 | 偶联物及其制备方法和用途 |
| WO2025230581A1 (en) * | 2024-05-02 | 2025-11-06 | Cidara Therapeutics, Inc. | Fc conjugates and uses thereof |
| WO2026055183A1 (en) * | 2024-09-03 | 2026-03-12 | Vir Biotechnology, Inc | Antiviral compositions and methods of using the same |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU732916C (en) | 1996-11-14 | 2002-06-06 | Biota Scientific Management Pty Ltd | Method and novel compounds for use therein |
| US6495580B1 (en) | 1998-01-29 | 2002-12-17 | Viropharma Incorporated | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases |
| AUPP913999A0 (en) | 1999-03-12 | 1999-04-01 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
| SI1196408T1 (en) | 1999-06-28 | 2005-02-28 | Janssen Pharmaceutica N.V. | Respiratory syncytial virus replication inhibitors |
| AUPR001000A0 (en) * | 2000-09-08 | 2000-10-05 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
| AUPR879701A0 (en) * | 2001-11-09 | 2001-12-06 | Biota Scientific Management Pty Ltd | Novel chemical compounds and their use |
| WO2004014316A2 (en) | 2002-08-09 | 2004-02-19 | Viropharma Incorporated | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases |
| CA2556752C (en) | 2004-02-23 | 2016-02-02 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| BRPI0615354A2 (pt) | 2005-08-19 | 2011-05-17 | Endocyte, Inc. | conjugado de liberação de fármaco de ligação de receptor, composição farmacêutica que o compreende, bem como seu uso |
| EP2158318A2 (en) | 2007-05-14 | 2010-03-03 | Biogen Idec MA, Inc. | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
| JP2012517447A (ja) | 2009-02-10 | 2012-08-02 | ザ スクリプス リサーチ インスティチュート | 化学的にプログラムされたワクチン接種法 |
| AU2011250970B2 (en) | 2010-05-10 | 2016-12-15 | Sinica, Academia | Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses |
| PT3012258T (pt) | 2010-06-24 | 2018-12-14 | Gilead Sciences Inc | Composição farmacêutica compreendendo um derivado de pirazolo[1,5-a]pirimidina como agente antiviral |
| EP3415528B1 (en) | 2011-04-13 | 2021-05-26 | Bristol-Myers Squibb Company | Fc fusion proteins comprising novel linkers or arrangements |
| US8871756B2 (en) | 2011-08-11 | 2014-10-28 | Hoffmann-La Roche Inc. | Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease |
| TW201817744A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| US9834597B2 (en) | 2012-09-21 | 2017-12-05 | The Regents Of The University Of California | Modified FC polypeptides, FC conjugates, and methods of use thereof |
| MY172021A (en) | 2012-10-16 | 2019-11-12 | Janssen Sciences Ireland Uc | Rsv antiviral compounds |
| WO2014145016A2 (en) | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Il-22 polypeptides and il-22 fc fusion proteins and methods of use |
| AR096891A1 (es) | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo |
| JP6211195B2 (ja) | 2013-08-12 | 2017-10-11 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 呼吸器合胞体ウイルス感染症の処置および予防のための新規アザ−オキソ−インドール |
| TWI671299B (zh) | 2014-04-14 | 2019-09-11 | 愛爾蘭商健生科學愛爾蘭無限公司 | 作為ｒｓｖ抗病毒化合物之螺脲化合物 |
| WO2017046625A1 (en) | 2015-06-25 | 2017-03-23 | Cube Biotech Gmbh | New chelators for affinity purification of recombinant proteins |
| WO2018006063A1 (en) | 2016-07-01 | 2018-01-04 | Cidara Therapeutics, Inc. | Compositions and methods for the treatment of bacterial infections |
| US20230190950A1 (en) * | 2017-01-06 | 2023-06-22 | Cidara Therapeutics, Inc. | Compositions and methods for the treatment of bacterial infections |
| BR112021004266A2 (pt) | 2018-09-06 | 2021-08-03 | Cidara Therapeutics, Inc. | conjugados, população de conjugados, composição farmacêutica e métodos para o tratamento de um sujeito com uma infecção viral e para o tratamento profilático |
| WO2020252396A1 (en) | 2019-06-13 | 2020-12-17 | Cidara Therapeutics, Inc. | Compositions and methods for the treatment of respiratory syncytial virus |
| AU2020291469A1 (en) | 2019-06-13 | 2022-02-10 | Cidara Therapeutics, Inc. | Compositions and methods for the treatment of human immunodeficiency virus |
| TWI861205B (zh) | 2019-09-06 | 2024-11-11 | 美商席達拉醫療有限公司 | 用於治療病毒感染之組合物及方法 |
| CA3211494A1 (en) * | 2021-03-11 | 2022-09-15 | Leslie W. Tari | Protein-drug conjugates for antiviral therapy |
-
2020
- 2020-09-07 TW TW109130663A patent/TWI861205B/zh active
- 2020-09-08 CR CR20220138A patent/CR20220138A/es unknown
- 2020-09-08 JP JP2022514998A patent/JP7667139B2/ja active Active
- 2020-09-08 WO PCT/US2020/049772 patent/WO2021046549A1/en not_active Ceased
- 2020-09-08 CA CA3153359A patent/CA3153359A1/en active Pending
- 2020-09-08 KR KR1020227011190A patent/KR20220088527A/ko active Pending
- 2020-09-08 AU AU2020342649A patent/AU2020342649B2/en active Active
- 2020-09-08 CN CN202080077368.1A patent/CN114980933B/zh active Active
- 2020-09-08 IL IL290792A patent/IL290792B1/en unknown
- 2020-09-08 CN CN202510048861.5A patent/CN120168655A/zh active Pending
- 2020-09-08 PH PH1/2022/550505A patent/PH12022550505A1/en unknown
- 2020-09-08 MX MX2022002728A patent/MX2022002728A/es unknown
- 2020-09-08 PE PE2022000373A patent/PE20221443A1/es unknown
- 2020-09-08 EP EP20860243.3A patent/EP4025256A4/en active Pending
-
2021
- 2021-03-05 US US17/194,093 patent/US20210220478A1/en not_active Abandoned
- 2021-04-21 US US17/236,745 patent/US11510992B1/en active Active
-
2022
- 2022-03-03 CL CL2022000531A patent/CL2022000531A1/es unknown
- 2022-03-17 CO CONC2022/0003078A patent/CO2022003078A2/es unknown
- 2022-03-30 ZA ZA2022/03681A patent/ZA202203681B/en unknown
- 2022-04-05 EC ECSENADI202226797A patent/ECSP22026797A/es unknown
- 2022-08-15 US US17/887,776 patent/US12427200B2/en active Active
-
2025
- 2025-04-10 JP JP2025065195A patent/JP2025108559A/ja active Pending
- 2025-07-23 US US19/277,976 patent/US20260108618A1/en active Pending
- 2025-11-07 AU AU2025263868A patent/AU2025263868A1/en active Pending